Ken Griffin Next Cure, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Next Cure, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 245,476 shares of NXTC stock, worth $378,033. This represents 0.0% of its overall portfolio holdings.
Number of Shares
245,476
Previous 200
122638.0%
Holding current value
$378,033
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding NXTC
# of Institutions
48Shares Held
16.1MCall Options Held
10.5KPut Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA2.67MShares$4.11 Million0.35% of portfolio
-
Logos Global Management LP San Francisco, CA1.93MShares$2.96 Million0.4% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.36MShares$2.09 Million0.44% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.14MShares$1.76 Million0.06% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.13MShares$1.75 Million0.0% of portfolio
About NextCure, Inc.
- Ticker NXTC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,748,800
- Market Cap $42.7M
- Description
- NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...